2020 Volume 29 Issue 2 Pages 93-98
The first commercially available endograft for the treatment of an abdominal aortic aneurysm (AAA) was approved in Japan in 2006. Recently, endovascular aneurysm repair (EVAR) has been developed as a standard procedure for AAA. However, several trials have reported that there was no advantage of EVAR in long-term outcomes compared with open repair. It is necessary to understand device characteristics and to perform accurate procedure, in order to stabilize long term results. In this paper, I describe the tips and pitfalls for EVAR.